

Claims

1. Use of a molecule that inhibits the expression and/or activity of prominin-1 for the manufacture of a medicament for treatment of pathological angiogenesis.

5

2. Use of a molecule according to claim 1 wherein said molecule is chosen from the list comprising an antibody or any fragment thereof, a small molecule, an RNA aptamer, a peptide, a ribozyme, anti-sense nucleic acids and siRNA.

10

3. A method to identify molecules that comprise a region that specifically binds to prominin-1 comprising:

- exposing prominin-1 or nucleic acids encoding prominin-1 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined,

15

- determining binding or hybridising of said molecule(s) to prominin-1 or nucleic acids encoding prominin-1, and
- monitoring said pathological angiogenesis when administering said molecules as a medicament.